REFERENCES
- Nalluri S. R., Chu D., Keresztes R., et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. Jama 2008; 300: 2277–85
- Khorana A. A., Francis C. W., Culakova E., et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110: 2339–46
- Chew H. K., Wun T., Harvey D., et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458–64
- Khorana A. A., Francis C. W., Culakova E., et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632–634
- Kuderer N. M., Francis C. W., Culakova E., et al. Venous thromboembolism represents a major risk factor for early all-cause mortality in patients receiving cancer chemotherapy. J Clin Oncol 2008; 26
- Prandoni P., Lensing A. W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484–8
- Ambrus J. L., Ambrus C. M., Mink I. B., et al. Causes of death in cancer patients. J Med 1975; 6: 61–4
- Shen V. S., Pollak E. W. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?. South Med J 1980; 73: 841–3
- O'Connell C. L., Boswell W. D., Duddalwar V., et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 2006; 24: 4928–32
- Lyman G. H., Khorana A. A., Falanga A., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490–505
- Khorana A. A., Kuderer N. M., Culakova E., et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902–7
- Bluff J. E., Brown N. J., Reed M. W., et al. Tissue factor, angiogenesis and tumour progression. Breast Cancer Res 2008; 10: 204
- Bobek V., Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004; 58: 213–9
- Winter P. C. The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. Hematol Oncol 2006; 24: 126–33
- Zacharski L. R., Henderson W. G., Rickles F. R., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984; 53: 2046–52
- Kuderer N. M., Khorana A. A., Lyman G. H., et al. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007; 110: 1149–61
- Falanga A. The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest 2009; 27: 105–15